Clinical trial
Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion
NCT00406471 · Greater Houston Retina Research, Other · Completed
Key facts
| NCT number | NCT00406471 |
|---|---|
| Title | Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion |
| Official title | Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion |
| Lead sponsor | Greater Houston Retina Research, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Ischemic Central Retinal Vein Occlusion |
| Intervention type | Drug |
| Interventions | Ranibizumab (Lucentis) |
| Enrollment | 20 |
| Start date | May 1, 2005 |
| Primary completion | Jan 1, 2011 |
| Completion | Jan 1, 2011 |
| First posted | Dec 4, 2006 |
| Last update posted | Mar 14, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: